Healthcare

We create and invest in leading companies in therapeutics, medtech, and health IT & services.

33

Thirty three products and drugs approved

With another 12 drugs in phase 3. Typically, only 1 in 5,000 drugs makes it from idea to market.

29

Twenty nine companies created from scratch

If we can't find a company solving an important problem, we create one ourselves - just like we did with Innovent, Denali, Beam and Prime Medicine to name a few.

$2.5B

Over two and a half billion dollars over nine funds

Without the pressure of fundraising from outside investors, we're privileged to champion companies that help heal the world.

Category

Region

Status

  • Insilico specializes in artificial intelligence for drug discovery, biomarker development and aging research. Learn more at www.insilico.com.

    • Category

      • Therapeutics

    • Status

      • Private

    • Location

      Hong Kong

    • Year Invested

      2019

    • Team

      Chong Xu, Ph.D.

  • Invetx is a pioneer in creating novel, protein-based animal health therapeutics to transform standards of care in veterinary medicine. The company leverages a best-in-class, fully integrated biotechnology platform for the discovery, development, and manufacturing of veterinary monoclonal antibodies, and is developing a diverse product pipeline addressing chronic and severe diseases in the veterinary species. learn more at www.invetx.com.

  • Iora Health is building a different kind of health system to deliver high impact, relationship based care. Iora Health was acquired by One Medical in September 2021.

  • Ironwood Pharmaceuticals (NASDAQ:IRWD) developed  linaclotide, a first-in-class therapy that received FDA approval for both irritable bowel syndrome and chronic constipation. Learn more at www.ironwoodpharma.com.

    • Category

      • Therapeutics

    • Status

      • Public

    • Location

      Cambridge, MA

    • Year Invested

      2002

    • Team

      Stephen Knight, M.D.

  • Ivenix is dedicated to eliminating infusion-related patient harm, uniquely positioned at the crossroads of healthcare IT and infusion delivery. Ivenix was acquired by Fresenius Kabi in 2022.

  • J-Pharma is a clinical stage biopharmaceutical company with a mission to create and develop novel pharmaceuticals. J-Pharma is conducting trials in Japan for advanced stage cancer patients. Learn more at j-pharma.com.

  • K36 Therapeutics was established with the mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies. Its vision is to create breakthrough therapies for the unmet medical needs of cancer patients worldwide.

  • KnowYourself is a digital health company that is focused on promoting mental wellness in China.

  • Kyruus uses the science of data-driven clinical matching to ensure that patients are being matched to the right provider and enabling healthcare systems to coordinate care delivery across their provider networks. Learn more at www.kyruus.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Boston, MA

    • Year Invested

      2012

    • Team

      Jon Lim, Carl Byers

  • Laurus Labs (NSE:LAURUSLABS) is a leading manufacturer of Active Pharmaceutical Ingredients (API) for anti-retroviral (HIV-AIDS), oncology, nutraceutical and several other products, with a customer base that spans top-tier generic pharmaceutical companies in India and abroad. Learn more at www.lauruslabs.com.

  • LenoMed is a company that develops and produces insulin pumps.  Learn more at www.lenomed.com.cn.

    • Category

      • MedTech

    • Status

      • Private

    • Location

      Shanghai, China

    • Year Invested

      2018

    • Team

      Chong Xu, Ph.D.

  • Leyden Labs platform targets commonalities of viral families to protect humanity from known and future viruses. Learn more at www.leydenlabs.com.

  • Liazon is a provider of web-based private benefits exchanges to small and medium-sized businesses. Liazon was acquired by Towers Watson in 2013. Learn more at www.liazon.com.

    • Category

      • Health IT/Services

    • Status

      • Acquired

    • Location

      Buffalo, NY

    • Year Invested

      2012

    • Team

      Jon Lim

  • LigoCyte Pharmaceuticals was a vaccine discovery and development company with a first-in-class vaccine for norovirus, a pathogen that is a leading cause of viral gastroenteritis (stomach flu). LigoCyte Pharmaceuticals was acquired by Takeda.

    • Category

      • Therapeutics

    • Status

      • Acquired

    • Location

      Bozeman, MT

    • Year Invested

      2008

    • Team

      Stephen Knight, M.D.

  • Lumere (formerly Procured Health) is an organization comprised of clinicians, researchers, pharmacists and strategic thought leaders focused on helping health systems eliminate unwarranted clinical variation and cut unnecessary costs—specifically related to device and drug selection and utilization. This company was acquired by Global Healthcare Exchange (GHX) in 2020.

    • Category

      • Health IT/Services

    • Status

      • Acquired

    • Location

      Chicago, IL

    • Year Invested

      2012

    • Team

      Jon Lim

  • LunaDNA is the first health and genomic data platform owned by its community of personal health information donors. LunaDNA empowers individuals to share their health data for medical research and the greater good of the community. As community owners in the LunaDNA platform, members share in the value created from health discoveries and medical breakthroughs. LunaDNA was created by the privately-owned Public Benefit Corporation, LunaPBC, founded in 2017 and headquartered in La Jolla, California. The LunaPBC team, investors, and advisors are renowned in the patient-advocacy, health, and science fields, including several former chief executives of Illumina, industry academics, and financial executives. Learn more at www.lunadna.com.

  • Madaket automates the manual, error-prone process of enrollment for healthcare providers and payers. The result is less paperwork and faster payments for hospitals, health systems, and private practices. Learn more at www.madakethealth.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Cambridge, MA

  • MDDF is a medical device company focused on the manufacturing, development, and commercialization of high quality, affordably priced cardiovascular and general surgery medical devices for the Chinese market.

     

    • Category

      • MedTech

    • Status

      • Private

    • Location

      Beijing, China

    • Year Invested

      2011

    • Team

      Kevin Chu

  • Medbanks (0314:HK) is building a data service platform for oncologists and cancer care centers in China. Learn more at www.medbanks.cn.

  • MediTrust Health is a provider of payment services for medical healthcare. The company is dedicated to helping patients solve their own medical payment problems through financial insurance, manage medical expenses more efficiently, and providing value to patients around medical finance, curative effect insurance, and drug benefits, helping patients manage their medical expenses. Learn more at www.meditrusthealth.com.

  • Medly Pharmacy is a full-service, digital pharmacy under parent company Medly Health that offers free same-day prescription delivery. Combining dedicated customer service with two generations of pharmacy expertise, Medly works with providers and patients to personalize every aspect of the care journey. Learn more at www.medly.com.

     

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      New York, NY

    • Year Invested

      2021

  • Medwell Ventures Private Unlimited (“Medwell”) is an operator of specialty home healthcare services in India. Learn more at www.medwellventures.com.

  • Menlo Therapeutics Inc. (NASDAQ: MNLO) is a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. Learn more at www.menlotherapeutics.com.

  • Mersana Therapeutics (NASDAQ:MRSN) has its lead product candidate, XMT-1536, in clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines. Learn more at www.mersana.com.

    • Category

      • Therapeutics

    • Status

      • Public

    • Location

      Cambridge, MA

    • Year Invested

      2005

    • Team

      Thomas Beck, M.D.

  • Metcela is a clinical-stage Kanagawa-based biotech company bringing cell-based therapies to heart failure patients. Learn more at www.metcela.com.

  • Modis Therapeutics, Inc. was formed in 2016 through a collaboration with academic experts in mitochondrial biology. The company’s lead program (MT1621) is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. Modis Therapeutics is headquartered in Oakland CA, with offices in New York City. Modis was acquired by Zogenix.

    • Category

      • Therapeutics

    • Status

      • Acquired

    • Location

      Oakland, CA

    • Year Invested

      2018

    • Team

      Kevin Chu

  • Nanos Medical develops, manufactures and markets minimally invasive interventional therapy medical devices in the field of ENT, cardiovascular and others. Learn more at www.nanosmedical.com.

    • Category

      • MedTech

    • Status

      • Private

    • Location

      Shanghai, China

    • Year Invested

      2019

    • Team

      Chong Xu, Ph.D.

  • Nebula Genomics is a human genome sequencing and health big data company on a mission to usher in the era of genomic sequencing by building a large and trusted genomic and health data marketplace for consumers, researchers and the medical community. Using blockchain to ensure that consumers maintain control of their data and are compensated for its use, the Nebula marketplace will aggregate a critical mass of rich genetic information that researchers can analyze in order to accelerate drug development, streamline clinical trials, and usher in the era of truly personalized medicine. Nebula Genomics was acquired by ProPhase Labs in 2021.

    • Category

      • Health IT/Services

    • Status

      • Acquired

    • Location

      San Francisco, CA and Boston, MA

    • Year Invested

      2018

    • Team

      Carl Byers

  • Neumora Therapeutics, Inc. is a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. Neumora is redefining neuroscience research and development with a data-driven precision neuroscience platform to cut through brain disease heterogeneity to match the right patient populations to targeted therapeutics. The Company’s precision data science platform integrates multiple data types to define patient subtypes through the development of Data Biopsy Signatures™ and Precision Phenotypes™.  Learn more at www.neumoratx.com.

  • NeuroSmart is an operator of an education and research center focusing on autism. The company helps patients with autism through scientific research and early intervention application, providing families with a comprehensive scientific family intervention program.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Zhejiang, China

    • Year Invested

      2021

    • Team

      Chong Xu, Ph.D., Alex Wong

  • NextWave Pharmaceuticals is a specialty pharmaceutical company seeking to create and promote differentiated products in the pediatric market. NextWave Pharmaceuticals was acquired by Pfizer.

  • NFlection Therapeutics is a biopharmaceutical company focused on the development of therapies for Neurofibromatosis 1 (NF1), and other disorders. Learn more at www.nflectionrx.com.

  • NOCD is the #1 telehealth provider for the treatment of obsessive-compulsive disorder (OCD) and the leading Community-Driven Therapy company. The company helps people reclaim their lives with clinically proven OCD treatment by removing barriers to care, and by reducing the stigma associated with OCD. Inside the NOCD platform, members can quickly access a national network of licensed therapists that specialize in Exposure and Response Prevention (ERP), the “gold standard” for OCD treatment. Learn more at www.treatmyocd.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Chicago, IL

    • Year Invested

      2021

    • Team

      Jon Lim, Brett Cook

  • Nocion Therapeutics, a neuroinflammation and analgesic company discovering and developing novel pharmaceutical treatments for various indications including pain, cough and itch.  Learn more at www.nociontx.com.

    • Category

      • Therapeutics

    • Status

      • Private

    • Location

      Cambridge, MA

    • Year Invested

      2019

    • Team

      Jessica Alston, Ph.D.

  • NodThera is a biotech engaged in innate immune/inflammasome research. Our leading project is focused on developing inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases. Learn more at www.nodthera.com

  • Notable is an AI powered healthcare company that puts appointments on autopilot. By analyzing historical patterns of practice, Notable proactively automates away hundreds of manual repetitive tasks like adding diagnoses, orders, templates, billing codes, and more. Learn more at www.notablehealth.com.

  • NovaMed Pharmaceuticals is a revenue-generating specialty pharmaceutical company focused on the commercialization of branded innovative therapies for diseases with high unmet medical need in China, including oncology, urology, and cardiovascular.  NovaMed was acquired by SciClone.

    • Category

      • Therapeutics

    • Status

      • Acquired

    • Location

      Shanghai, China

    • Year Invested

      2007

  • Orchard Therapeutics (NASDAQ:ORTX) Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies. Learn more at www.orchard-tx.com.

  • OriGynMED is a developer of medical devices designed for women’s health. The company is mainly engaged in developing various gynecology medical devices such as hysterectomy cold knife and functional hysteroscope, enabling client to improve treatment effect. Learn more at www.origynmed.com.

  • Orient Speech Therapy Limited (“OST”) is a Hong-Kong based healthcare services provider that operates a chain of private speech therapy clinics in China. Learn more at www.dfqy.com.

  • Oviva is a new type of healthcare provider using technology to scale the dietitian workforce to help meet the growing number of patients with diet-related health conditions. Learn more at www.oviva.com/uk/.

  • Owkin combines life-science and machine learning expertise to make drug development and clinical trial design more targeted and more cost effective. Owkin’s machine learning algorithms create models that predict disease evolution and treatment outcomes. These predictive models are implemented in clinical trials for enhanced analysis, surrogate endpoints, patient stratification, patient selection, and high-value subgroup identification. The impact of this research is faster discovery of better treatments at a lower cost. Learn more at www.owkin.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      New York, NY

    • Year Invested

      2019

    • Team

      Alex Pasteur, Ph.D.

  • OZiva is a plant-based Clean Nutrition Brand. The brand’s core differentiator lies in building a nutrition & fitness ecosystem that combines the best of ancient sciences such as Ayurveda, modern micronutrients, and an instantaneous digital community altogether.  Learn more at www.oziva.in.

  • Papaya Payments is a free and easy way to pay your bills. Just snap a photo of a paper bill and Papaya will automatically validate it and facilitate your payment. Learn more at www.papayapayments.com.

    • Category

      • FinTech
      • Health IT/Services

    • Status

      • Private

    • Location

      Los Angeles, CA

    • Year Invested

      2018

    • Team

      Jay Farber, David Jegen

  • Paradigm is rebuilding the clinical research ecosystem by creating a platform that enables equitable access to trials for all patients, while enhancing trial efficiency and reducing the barriers to participation for healthcare providers. Paradigm aims to break down barriers across the trial ecosystem through one seamless infrastructure implemented at healthcare provider organizations, bringing potentially life-saving therapies to patients faster. Learn more: www.paradigm.inc.

  • PatientPing is a care coordination platform that reduces the cost of healthcare by seamlessly connecting providers to coordinate patient care. Patient Ping was acquired by Appriss Health in 2021.

    • Category

      • Health IT/Services

    • Status

      • Acquired

    • Location

      Boston, MA

    • Year Invested

      2015

    • Team

      Jon Lim, Brett Cook

  • Patina is reinventing primary care for older adults and those who care for them, so everyone gets the healthcare and aging experience they deserve. Learn more at www.patinahealth.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Bala Cynwyd, PA

    • Year Invested

      2021

    • Team

      Carl Byers, Brett Cook

  • Pediatrix Therapeutics is a pharmaceutical company focused on the field of pediatrics by developing and introducing effective and clinically proven children’s medicines to provide Chinese children and families with high-quality and affordable treatment options

  • Peptone is an innovative drug discovery company applying advanced biophysics, atomic-level experimental approaches, cutting-edge supercomputing and machine learning to the challenge of biopharmaceutical research and development. By bringing these proprietary approaches together, we are exploring the world of intrinsically disordered proteins (IDPs) – proteins without a fixed structure that play a significant role in health and disease – opening up the possibility of novel therapeutics against an entire class of high value and previously undruggable targets. Learn more at peptone.io.

  • PharmEasy is one of India’s largest healthcare delivery platforms. The company helps patients connect with local pharmacy stores and diagnostic centers in order to fulfill their medical needs. Learn more at www.pharmeasy.in.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Mumbai, India

    • Year Invested

      2018

    • Team

      Carl Byers

  • Plasmagen is an Indian biopharma company that specializing exclusively in Plasma Protein Therapy. Learn more at www.plasmagen.in.

  • Precision Biosciences (NASDAQ:DTIL) is developing a gene-editing platform based on their proprietary ARCUS nuclease for multiple applications with a focus on human therapeutics. Learn more at www.precisionbiosciences.com.

    • Category

      • Therapeutics

    • Status

      • Public

    • Location

      Durham, NC

    • Year Invested

      2015

  • Prime Medicine (NASDAQ: PRME) is a biotechnology company founded to deliver on the promise of Prime Editing, a versatile gene editing technology that can truly “search and replace” to restore normal genetic function and address the fundamental causes of disease. Prime Medicine envisions a world where Prime Editing can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients and shaping the future of gene editing. Learn more at www.primemedicine.com.

     

    • Category

      • Therapeutics

    • Status

      • Public

    • Location

      Cambridge, MA

    • Year Invested

      2019

    • Team

      Stephen Knight, M.D.

  • Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company, is developing innovative therapies for neuropsychiatric disorders. Learn more at www.promentispharma.com.

    • Category

      • Therapeutics

    • Status

      • Private

    • Location

      Milwaukee, Wisconsin

    • Year Invested

      2016

    • Team

      Robert Weisskoff, Ph.D.

  • The migration of rapid, accurate molecular testing to “the edge” in point-of-care and at-home settings is becoming a foundational pillar of quickly evolving healthcare delivery strategies globally.  Proof Diagnostics will contribute to this changing landscape by delivering CRISPR-based solutions, starting with a COVID-19 test, that are simple, rapid and affordable for everyone. Learn more at Proofdx.com.

  • The Protenus healthcare compliance analytics platform uses artificial intelligence to help partner hospitals make decisions about how to better protect their data, their patients, and their institutions. Learn more at www.protenus.com.

  • Proteostasis Therapeutics (NASDAQ: PTI)  is a drug discovery company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing. Learn more at www.proteostasis.com.

    • Category

      • Therapeutics

    • Status

      • Public

    • Location

      Cambridge, MA

    • Year Invested

      2008

    • Team

      Stephen Knight, M.D.

  • Proximie is a technology platform that uses a combination of machine learning, artificial intelligence and augmented reality to allow clinicians to virtually ‘scrub in’ and collaborate with each other from anywhere in the world.  Learn more at proximie.com.

  • Pulmocide is a biopharmaceutical company with a mission to treat common acute and chronic respiratory tract infections associated with serious complications and devastating effects on patients’ quality of life. Learn more at www.pulmocide.com.

  • Quartet Health is developing care coordination software and services designed to improve clinical outcomes and reduce the cost of care for patients where behavioral health is the primary or a comorbid condition. Learn more at www.quartethealth.com

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      New York, NY

    • Year Invested

      2015

    • Team

      Carl Byers

  • Rallybio (NASDAQ: RLYB) is a biopharmaceutical company focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Learn more at www.rallybio.com.

  • RareCyte offers Precision Biology™ solutions focused on multiplexed analysis of cells and tissue with applications in both research and clinical diagnostics. The Company has deep experience in developing advanced precision life science systems used in cutting-edge labs worldwide. RareCyte customers perform innovative research, bring new therapeutics to market, and perform a wide range of single cell applications in oncology and disease research. Learn more at www.rarecyte.com.

  • RareStone (formerly Citrine Medicine) is a rare disease-focused therapeutics company focused on the Greater China market that was co-founded by Eight Roads Ventures, F-Prime Capital and Vivo Capital. RareStone is dedicated to improving the lives of rare disease patients by making diagnosis and essential treatments available and accessible for those who need them. Learn more at www.rarestonegroup.com.

  • REDPINE is a medical technology company that provides complete solutions for medical business. It focuses on the research and development and production of single-use Class III medical devices, initially endoscopes for urology and gynecology. Learn more at en.gzredpine.com.

  • ReGenX Biosciences (NASDAQ: RGNX)  is a leading AAV (adeno-associated virus) gene therapy company with a broad platform technology based on its proprietary NAV vector technology platform Learn more at www.regenxbio.com.

    • Category

      • Therapeutics

    • Status

      • Public

    • Location

      Washington, D.C.

    • Year Invested

      2013

  • RespiVert was a drug discovery and development company focused on inhaled therapies for severe respiratory disease. RespiVert was acquired by Centocor Ortho Biotech – a division of Johnson & Johnson.

    • Category

      • Therapeutics

    • Status

      • Acquired

    • Location

      London, UK

    • Year Invested

      2007

    • Team

      Stephen Knight, M.D.

  • Rialtic is an enterprise software platform empowering health insurers and healthcare providers to run their most critical business functions. Rialtic’s best-in-class payment accuracy product brings programs in-house and helps health insurance companies gain total control over processes that have been managed by disparate and misaligned vendors. Currently working with leading healthcare insurers and providers, the company is tackling a $1 trillion problem to reduce costs, increase efficiency and improve quality of care. Learn more at www.rialtic.io.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Atlanta, GA

    • Year Invested

      2020

    • Team

      Carl Byers

  • RIGImmune is a platform biopharmaceutical company developing a novel investigational class of RNA immunotherapies termed “SLRs” for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The RIGImmune development candidates act to specifically modulate RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The lead development candidate at RIGImmune is RIG-101.

    The company was co-founded by the prominent Yale University professors, Anna Marie Pyle, Ph.D. and Akiko Iwasaki, Ph.D., who currently serve as scientific advisors to the company. Dr. Pyle co-discovered the RIG-I receptor family and conducted many of the first structural and biochemical investigations on the cytosolic protein, RIG-I. Dr. Pyle is also a specialist in RNA structure and design. She designed the stem-loop RNA therapeutics (SLR) for selective targeting of RIG-I using crystal structure data of RIG-I complexed with RNA and developed them as antitumor and anticancer compounds in collaboration with Dr. Iwasaki, whose expertise in mucosal immunity has been highly sought during the COVID-19 pandemic.

    RIGImmune is a UConn Technology Incubation Program (TIP) company located in Farmington, CT, was founded by Yale scientists, and has an experienced management team of successful biotech entrepreneurs and world-renowned scientists. Learn more at rigimmune.com.

  • Rippl is a new kind of mental health company focused on seniors and obsessed with its clinicians. Seniors with mental health challenges, especially neurocognitive conditions like Alzheimer’s disease and other dementias, are overlooked and under cared for, often without access to high quality, real-time, practical care. Leveraging a value-based approach, disruptive technology, and a relentless focus on empowering and enabling its clinicians, Rippl is pioneering a new care model to dramatically expand access to high quality, wraparound mental health care for seniors, their families, and caregivers. Rippl provides 24/7 support and personalized care when and where they need it – on the phone, online or in their living rooms. Learn more at www.ripplcare.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Seattle, WA

    • Year Invested

      2022

    • Team

      Jon Lim, Brett Cook

  • Sana Biotechnology, Inc. (NASDAQ:SANA) is focused on creating and delivering engineered cells as medicine for patients. We are a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and changes how we approach treating disease. Learn more about Sana at www.sana.com.

  • Semma Therapeutics is a regenerative medicine company founded to develop transformative stem cell-derived therapies to provide a functional cure for patients with diabetes. This company was acquired by Vertex in 2019.

  • Shift Bioscience (Shift) is a Cambridge, UK-based biotechnology company focused on safe cellular reprogramming for rejuvenation. The company leverages a proprietary cellular age clock and an active machine learning approach to discover novel factors for safer cellular rejuvenation without the use of pluripotency-inducing reprogramming genes. Shift aims to enable the development of reprogramming-based therapeutics to prevent and treat age-associated diseases. Learn more at www.shiftbioscience.com.

  • Silexon is an emerging AI-empowered technology company which aims to create an open AI platform for strategic collaboration in order to facilitate data-driven life science research and empower drug R&D process, and ultimately provide patients with greater access to innovative drugs for unmet medical needs.  Learn more at www.silexon.tech.

  • Singular Genomics (NASDAQ: OMIC) is developing a new next generation sequencing platform. Learn more at www.singulargenomics.com.

  • Sironax is a developer of pharmaceuticals for inflammatory and neuro-degenerative diseases. The company researches apoptosis and other cell death pathways to develop quality pharmaceuticals, enabling healthcare professionals to prescribe advanced treatments to their patients.

  • 66nao provides a cloud based platform for digital brain assessment and training. Learn more at www.66nao.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Beijing, China

    • Year Invested

      2016

  • Skyline Therapeutics (formerly Geneception) is a fully-integrated gene and cell therapy based in Hangzhou and Shanghai, China.  Founded by F-Prime Capital, Eight Roads Ventures China and Lilly Asia Ventures in 2018, Skyline’s mission is to become a preeminent gene and cell therapy company, working to deliver world-class therapeutics for patients in China and globally.

  • SonderMind enables consumers to quickly find and access a trusted, well-matched therapist, while enabling therapists to focus on providing excellent patient care, not worrying about administrative and billing issues.  Learn more at www.sondermind.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Denver, CO

    • Year Invested

      2020

    • Team

      Carl Byers

  • SpectrumAi is a digital health company innovating Autism care to increase access to high-quality ABA therapy for kids on the spectrum around the world. With support from industry veterans in technology and healthcare, SpectrumAi is working with global clinical leaders in ABA therapy, parents, and payers to modernize. Learn more at www.spectrumai.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Los Angeles, CA

    • Year Invested

      2022

    • Team

      Carl Byers

  • Spry is a purpose built platform for the physical rehabilitation industry. It helps therapists streamline care delivery, increase patient inflow and reduce administrative costs while also helping patients improve outcomes by making it easy to understand and follow care plans. Spry has been able to achieve this by using physical rehabilitation specific workflows, advanced computer vision technology and new age product design paradigms. Learn more: www.sprypt.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Mumbai, India

    • Year Invested

      2022

    • Team

      Carl Byers

  • Stride Health is an early-stage healthcare IT company developing a multi-carrier, private health insurance marketplace for the individual segment. Learn more at www.stridehealth.com.

    • Category

      • FinTech
      • Health IT/Services

    • Status

      • Private

    • Location

      San Francisco, CA

    • Year Invested

      2014

    • Team

      Carl Byers

  • Structure Therapeutics (NASDAQ: GPCR) is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs.  Learn more at www.structuretx.com.

  • Surface Oncology (NASDAQ:SURF) is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD73, CD39, IL-27 and CD47.  Learn more at www.surfaceoncology.com.

  • Symbiomix developed the first oral, single dose treatment in the United States for bacterial vaginosis (BV), a common gynecological infection that increases the risk of serious health problems. Symbiomix was acquired by Lupin Pharmaceuticals. Learn more at www.symbiomix.com.

    • Category

      • Therapeutics

    • Status

      • Acquired

    • Location

      Newark, NJ

    • Year Invested

      2013

    • Team

      Thomas Beck, M.D.

  • TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven and physics-based high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution. Learn more at www.tandemai.com.

  • TCT Medical is a diagnostic company based in China which provides high quality diagnostic tests, primarily in the women’s health arena. TCT Medical was acquired by Hologic.

    • Category

      • MedTech

    • Status

      • Acquired

    • Location

      Beijing, China

    • Year Invested

      2009

    • Team

      Stephen Knight, M.D.

  • Tempest Therapeutics is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways. Learn more at www.tempesttx.com.

  • Tetraphase (NASDAQ: TTPH)  is a biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections; its lead product XERAVATM (eravacycline) is approved for the treatment of complicated intra-abdominal infections by the FDA and EMA. Learn more at www.tphase.com.

  • Topaz Pharmaceuticals is a specialty pharmaceutical company developing a topical prescription product, Sklice, for the treatment of head lice. Topaz Pharmaceuticals was acquired by Sanofi.

     

  • TraceLink the world’s largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes. Learn more at www.tracelink.com.

    • Category

      • Health IT/Services

    • Status

      • Private

    • Location

      Wakefield, MA

    • Year Invested

      2015

    • Team

      Jon Lim